Cargando…

Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial

OBJECTIVES: The PIRADS Steering Committee has called for “higher quality data before making evidence-based recommendations on MRI without contrast enhancement as an initial diagnostic work up,” however, recognizing biparametric (bp) MRI as a reasonable option in a low-risk setting such as screening....

Descripción completa

Detalles Bibliográficos
Autores principales: Wallström, Jonas, Geterud, Kjell, Kohestani, Kimia, Maier, Stephan E., Månsson, Marianne, Pihl, Carl-Gustaf, Socratous, Andreas, Arnsrud Godtman, Rebecka, Hellström, Mikael, Hugosson, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523442/
https://www.ncbi.nlm.nih.gov/pubmed/33890152
http://dx.doi.org/10.1007/s00330-021-07907-9
_version_ 1784585301566423040
author Wallström, Jonas
Geterud, Kjell
Kohestani, Kimia
Maier, Stephan E.
Månsson, Marianne
Pihl, Carl-Gustaf
Socratous, Andreas
Arnsrud Godtman, Rebecka
Hellström, Mikael
Hugosson, Jonas
author_facet Wallström, Jonas
Geterud, Kjell
Kohestani, Kimia
Maier, Stephan E.
Månsson, Marianne
Pihl, Carl-Gustaf
Socratous, Andreas
Arnsrud Godtman, Rebecka
Hellström, Mikael
Hugosson, Jonas
author_sort Wallström, Jonas
collection PubMed
description OBJECTIVES: The PIRADS Steering Committee has called for “higher quality data before making evidence-based recommendations on MRI without contrast enhancement as an initial diagnostic work up,” however, recognizing biparametric (bp) MRI as a reasonable option in a low-risk setting such as screening. With bpMRI, more men can undergo MRI at a lower cost and they can be spared the invasiveness of intravenous access. The aim of this study was to assess cancer detection in bpMRI vs mpMRI in sequential screening for prostate cancer (PCa). METHODS: Within the ongoing Göteborg PCa screening 2 trial, we assessed cancer detection in 551 consecutive participants undergoing prostate MRI. In the same session, readers first assessed bpMRI and then mpMRI. Four targeted biopsies were performed for lesions scored PIRADS 3–5 with bpMRI and/or mpMRI. RESULTS: Cancer was detected in 84/551 cases (15.2%; 95% CI: 12.4–18.4) with mpMRI and in 83/551 cases (15.1%; 95% CI: 12.3–18.2%) with bpMRI. The relative risk (RR) for cancer detection with bpMRI compared to mpMRI was 0.99 (95% one-sided CI: > 94.8); bpMRI was non-inferior to mpMRI (10% non-inferiority margin). bpMRI resulted in fewer false positives, 45/128 (35.2%), compared to mpMRI, 52/136 (38.2%), RR = 0.92; 95% CI: 0.84–0.98. Of 8 lesions scored positive only with mpMRI, 7 were false positives. The PPV for MRI and targeted biopsy was 83/128 (64.8%) for bpMRI and 84/136 (61.8%) for mpMRI, RR = 1.05, 95% CI: 1.01–1.10. CONCLUSIONS: In a PSA-screened population, bpMRI was non-inferior to mpMRI for cancer detection and resulted in fewer false positives. KEY POINTS: • In screening for prostate cancer with PSA followed by MRI, biparametric MRI allows radiologists to detect an almost similar number of prostate cancers and score fewer false positive lesions compared to multiparametric MRI. • In a screening program, high sensitivity should be weighed against cost and risks for healthy men; a large number of men can be saved the exposure of gadolinium contrast medium by adopting biparametric MRI and at the same time allowing for a higher turnover in the MRI room. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-07907-9.
format Online
Article
Text
id pubmed-8523442
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85234422021-10-22 Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial Wallström, Jonas Geterud, Kjell Kohestani, Kimia Maier, Stephan E. Månsson, Marianne Pihl, Carl-Gustaf Socratous, Andreas Arnsrud Godtman, Rebecka Hellström, Mikael Hugosson, Jonas Eur Radiol Urogenital OBJECTIVES: The PIRADS Steering Committee has called for “higher quality data before making evidence-based recommendations on MRI without contrast enhancement as an initial diagnostic work up,” however, recognizing biparametric (bp) MRI as a reasonable option in a low-risk setting such as screening. With bpMRI, more men can undergo MRI at a lower cost and they can be spared the invasiveness of intravenous access. The aim of this study was to assess cancer detection in bpMRI vs mpMRI in sequential screening for prostate cancer (PCa). METHODS: Within the ongoing Göteborg PCa screening 2 trial, we assessed cancer detection in 551 consecutive participants undergoing prostate MRI. In the same session, readers first assessed bpMRI and then mpMRI. Four targeted biopsies were performed for lesions scored PIRADS 3–5 with bpMRI and/or mpMRI. RESULTS: Cancer was detected in 84/551 cases (15.2%; 95% CI: 12.4–18.4) with mpMRI and in 83/551 cases (15.1%; 95% CI: 12.3–18.2%) with bpMRI. The relative risk (RR) for cancer detection with bpMRI compared to mpMRI was 0.99 (95% one-sided CI: > 94.8); bpMRI was non-inferior to mpMRI (10% non-inferiority margin). bpMRI resulted in fewer false positives, 45/128 (35.2%), compared to mpMRI, 52/136 (38.2%), RR = 0.92; 95% CI: 0.84–0.98. Of 8 lesions scored positive only with mpMRI, 7 were false positives. The PPV for MRI and targeted biopsy was 83/128 (64.8%) for bpMRI and 84/136 (61.8%) for mpMRI, RR = 1.05, 95% CI: 1.01–1.10. CONCLUSIONS: In a PSA-screened population, bpMRI was non-inferior to mpMRI for cancer detection and resulted in fewer false positives. KEY POINTS: • In screening for prostate cancer with PSA followed by MRI, biparametric MRI allows radiologists to detect an almost similar number of prostate cancers and score fewer false positive lesions compared to multiparametric MRI. • In a screening program, high sensitivity should be weighed against cost and risks for healthy men; a large number of men can be saved the exposure of gadolinium contrast medium by adopting biparametric MRI and at the same time allowing for a higher turnover in the MRI room. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-021-07907-9. Springer Berlin Heidelberg 2021-04-23 2021 /pmc/articles/PMC8523442/ /pubmed/33890152 http://dx.doi.org/10.1007/s00330-021-07907-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Urogenital
Wallström, Jonas
Geterud, Kjell
Kohestani, Kimia
Maier, Stephan E.
Månsson, Marianne
Pihl, Carl-Gustaf
Socratous, Andreas
Arnsrud Godtman, Rebecka
Hellström, Mikael
Hugosson, Jonas
Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
title Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
title_full Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
title_fullStr Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
title_full_unstemmed Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
title_short Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
title_sort bi- or multiparametric mri in a sequential screening program for prostate cancer with psa followed by mri? results from the göteborg prostate cancer screening 2 trial
topic Urogenital
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523442/
https://www.ncbi.nlm.nih.gov/pubmed/33890152
http://dx.doi.org/10.1007/s00330-021-07907-9
work_keys_str_mv AT wallstromjonas biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT geterudkjell biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT kohestanikimia biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT maierstephane biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT manssonmarianne biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT pihlcarlgustaf biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT socratousandreas biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT arnsrudgodtmanrebecka biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT hellstrommikael biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial
AT hugossonjonas biormultiparametricmriinasequentialscreeningprogramforprostatecancerwithpsafollowedbymriresultsfromthegoteborgprostatecancerscreening2trial